[1] | Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.Science278: 1295–1300. |
[2] | Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, et al. (1996). Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med334: 1011–1017. |
[3] | Gitura B, Joshi MD, Lule GN, Anzala O. (2007). Total lymphocyte count as a surrogate marker forCD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi. East Afr Med J. 84(10):466-72. |
[4] | Shah ZA, Rasool R, Siddiqi MA. (2013). Effect of highly active anti-retroviral therapy on CD3+/CD4+/AIDS. Res Hum Retroviruses. 9(4):691-7. |
[5] | Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. (1999) Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS, 13: 2251–2260. |
[6] | Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenroder O, Krausslich HG, Arts EJ (2010). Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: Impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J. Virol. 84: 9817–9830. |
[7] | Lesserman J, Petitto JM, Golden RN, et al. (2000). The impact of stressful life events, depression, social support, coping and cortisol on progression to AIDS. Am J Psychiatry; 157: 1221-1228. |
[8] | Dutschman GE, Bastow KF, Sarngadharan MG, Ting RY (1987). Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Mol Biol262: 2187–2189. |
[9] | Collazos J, Ibarra S, Mayo J. (2003). Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era. AIDS 2003; 17: 763–5. Del AJ, Petruckevitch A, Philip A et al. (1998). Disease progression and survival in HIV 1 infected Africans. AIDS, 12:1203-1209. |
[10] | Ward J, Bush J, Perkins M. (1989). The natural history of transfusion associated infection with human immunodeficiency virus. New Eng J Med,;321:947-952. |
[11] | Beltran S, Lescure F-X, Desailloud R, et al,. (2003). Increased prevalence of hypothyroidism among human immunodeficiency virus–infected patients a need for screening. Clin Infect Dis. 37:579–83. |
[12] | Ogundele M, Coulter J. (2003). HIV transmission through breastfeeding: problems and prevention. Ann Trop Paediatr; 23: 91-106. |
[13] | Madeddu G, Spanu A, Chessa F, et al. (2006). Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 64:375–83. |
[14] | Grappin, M., Piroth, L., Verge, L., Bruno, Sgro, C., Mack, G. Bulsson, M. Marielle, D, Michel, C., Pascal, P, H. (2000). Increasesd prevalence of subclinical hypothyroidism in HIV patients in treated with highly active antiretroviral therapy. AIDS 14 (80: 1070. |
[15] | Lanzafame M, Trevenzoli M, Faggian F, et al. (2002). Interaction between levothyroxine and indinavir in a patient with HIV infection. Infection 30: 54–5. |
[16] | Bongiovanni, M, Adorni, F., Casana, M. (2006). Subclinical hypothyroidism in HIV-infected subjects. Br Soc Antimicrob Chemotherapy 58 (5) : 1086-1089. |
[17] | Sellimeyer,, DE and Grunfeld, C. (2013). Endocrine and Metabolic Disturbances in Human Immunodeficiency Virus Infection and the Acquired Immune Deficiency Syndrome. Endocrine Reviews, 17 (5): 116-120. |
[18] | Lesserman J, Jackson ED, Petitto JM, et al., (1999). Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med.;61:397-406. |
[19] | Chopra, JC Nelson, DH Solomon, GN Beal (1971). Production of antibodies specifically binding triiodothyronine and thyroxine. J. Clin. Endocrinol. Metab, 32, 299–308. |
[20] | Hopton, M.R .and J S Harrop, J.S. (1986). Immunoradiometric assay of thyrotropin as a "first-line" thyroid-function test in the routine laboratory. Clinical Chemistry 32 (4): 691-693. |
[21] | Allain, C. C., Poon, L. S., Chan, C. S., Richmond, W., & Fu, P. C. (1974). Enzymatic determination of total serum cholesterol. Clin Chem., 20 (4):470–475. |
[22] | Roeschlau, P., Bernt, E., Gruber, W. (1974). Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem., 12 (5):226. |
[23] | Giovanni Bucolo1 and Harold David (1973). Quantitative Determination of Serum Triglycerides by the Use of Enzymes. Clinical Chemistry 19 ( 5) : 476-482. |
[24] | Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18 (6): 499–502. |
[25] | Zoeller RT, Bansal R, and Parris C. (2005). Bisphenol-A, an environmental contaminant that acts as a thyroid hormone receptor antagonist in vitro, increases serum thyroxine, and alters RC3/neurogranin expression in the developing rat brain. Endocrinology 146(2):607-612. |
[26] | Gandhi RT, Spritzler J, Chan E, et al. (2006). Effect of baseline- and treatmentrelated factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 42:426–34. |
[27] | Eagling VA, Back DJ, Barry MG. (1999). Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997, 44:190–194. |
[28] | Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E (2006). Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 80: 4909–4920. |
[29] | Madhu N. Rao, Kathleen Mulligan, Viva Tai, Michael J. Wen, Artem Dyachenko, Melissa Weinberg, Xiaojuan Li, Thomas Lang, Carl Grunfeld, Jean-Marc Schwarz, and Morris Schambelan (2013). Effects of Insulin-Like Growth Factor (IGF)-I/IGF-Binding Protein-3 Treatment on Glucose Metabolism and Fat Distribution in Human Immunodeficiency Virus-Infected Patients with Abdominal Obesity and Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism 96 (9): 2009—2023. |
[30] | Quirino T, Bongiovanni M, Ricci E, Chebat E, Carradori S, Martinelli C, Valsecchi L, Landonio S, Bini T, Bonfanti PSee comment in PubMed Commons below. (2004). Hypothyroidism in HIV-infected patients who have or have not received HAART. Clin Infect Dis.; 8(4):596-7. |
[31] | Del, A.J., Petruckevitch, A., Philip, A. et al., (1998). Disease progression and survival in HIV 1 infected Africans. AIDS 12: 1203-1209. |